04/24/2026
A landmark moment for hearing loss care - new possibilities for children born with OTOF‑related genetic hearing loss.
Otarmeni (DB‑OTO) has received FDA accelerated approval as the first gene therapy for genetic hearing loss, treating OTOF‑related disease in children and adults.
Clinician‑investigators Jay Rubinstein, MD, PhD; Jim Phillips, PhD; and Meg Meredith, AuD, CCC‑A, affiliated with Seattle Children’s Hospital, the UW Department of Otolaryngology–HNS, and the Virginia Merrill Bloedel Hearing Research Center, were among the study teams. Regeneron Pharmaceuticals has also announced that Otarmeni will be provided free of charge in the U.S., removing barriers to access for affected children and families.
🔗 Read more - https://investor.regeneron.com/news-releases/news-release-details/otarmenitm-lunsotogene-parvec-cwha-approved-fda-first-and-only